NOW AVAILABLE: For the Gout Market – A SnapShot analysis of HCP targeted promotional messaging and DTC initiatives for 2016.

The gout market expanded in 2016 with the entry of multiple new products, including the first branded pieces from AstraZeneca for Zurampic and Gensco Laboratories for ColciGel. Takeda continued to dominate this category in terms of volume, with Colcrys and Uloric providing a combined total of 69% of the promotional materials received. The majority of products focused on offering education and support, while Takeda highlighted treatment in patients with renal impairment, and new campaigns were premiered by most brands. Additional insights into marketing strategies and channel utilization are available with a subscription.

 

2016 Gout

 

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, our online database of virtually all digital and print promotion distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com